MDXH
MDxHealth S.A. (MDXH) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Durability
Revenue base remains small at $1.6 per share, limiting scale advantages.
Gross margin is solid at 57.7%, but operating margin is still negative at -16.6%.
No recent news indicates a catalyst for sustained top-line acceleration.
Profitability
Net margin remains deeply negative at -32.2%, showing the business is still unprofitable.
Return on invested capital is negative at -12.7%, indicating value destruction on capital deployed.
Return on equity is distortedly high at 4.0x due to negative equity, so it is not a reliable sign of profitability.
Financial Health
Current ratio is only 1.08, leaving limited liquidity cushion.
Cash ratio of 0.59 suggests the company is not highly cash-rich relative to short-term obligations.
Leverage metrics remain strained, with debt-to-assets at 64.3% and negative equity-related ratios.
Valuation
EV/Sales of 1.26 is not demanding on a revenue basis, but it is offset by weak profitability.
Negative earnings and cash flow make P/E and FCF-based valuation metrics unreliable.
The market appears to be pricing in a turnaround rather than current fundamentals.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MDxHealth S.A.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

